Sequenom Posts 27 Percent Q3 Revenue Growth as It Plans FDA Talks on T21 Test | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Sequenom reported after the close of the market Thursday that its third-quarter revenues increased 27 percent, as sales for both its consumables and MassArray instruments grew year over year.

The San Diego-based firm reported total revenues of $11.7 million for the three-month period ended Sept. 30, compared to revenues of $9.2 million for the third quarter of 2009. It beat analysts' consensus estimate of $11.3 million for the quarter.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.